At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 71 enrolled
Drug / intervention
Lunestadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety of Eszopiclone (Lunesta) in Nursing Home Patients
In Brief
A Phase 4 clinical trial evaluating Lunesta for Poor Quality Sleep. Completed, enrolled 71 participants.
Detailed Summary
The purpose of this study is to examine the effects of the sleep aid Lunesta (Eszopiclone), on older adults who reside in a nursing home and have poor sleep as determined by wrist actigraphy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPoor Quality Sleep
Countries--
CollaboratorsSumitomo Pharma America, Inc.
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedApr 2007
Primary CompletionJun 2008
Study CompletionDec 2010
TodayJul 2026
First PostedApr 17, 2007
Enrollment StartJun 1, 2005
Primary CompletionJun 1, 2008
Study CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 19.2 years ago
Interventions
Lunestadrug
Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4. Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4.